Search tips
Search criteria 


Logo of cdiJournal's HomeManuscript SubmissionAims and ScopeAuthor GuidelinesEditorial BoardHome
Clin Dev Immunol. 2013; 2013: 575936.
Published online 2013 May 23. doi:  10.1155/2013/575936
PMCID: PMC3677008

Postmenopausal Osteoporosis: The Role of Immune System Cells


In the last years, new evidences of the relationship between immune system and bone have been accumulated both in animal models and in humans affected by bone disease, such as rheumatoid arthritis, bone metastasis, periodontitis, and osteoporosis. Osteoporosis is characterized by low bone mass and microarchitectural deterioration of bone tissue with a subsequent increase in bone fragility and susceptibility to fractures. The combined effects of estrogen deprivation and raising of FSH production occurring in menopause cause a marked stimulation of bone resorption and a rapid bone loss which is central for the onset of postmenopausal osteoporosis. This review focuses on the role of immune system in postmenopausal osteoporosis and on therapeutic strategies targeting osteoimmunology pathways.

1. Introduction

In the last few years, there have been important advances in understanding the processes that regulate physiological and pathological bone turnover.

Moreover, a relationship between the immune system and bone has long been speculated, as bone loss is a common condition of autoimmune and inflammatory disorders [13]. In this respect, T cells have been recognized as key regulators of osteoclast (OC) and osteoblast (OB) formation and activity in different diseases, such as rheumatoid arthritis [4], bone metastasis [5, 6], periodontitis [7, 8], congenital adrenal hyperplasia (CAH) [911], and osteoporosis [12].

In this review we focus on the involvement of immune system in the pathogenesis of osteoporosis with particular regard to postmenopausal osteoporosis and on the new therapeutic advances in its treatment.

2. Osteoporosis

To maintain a structural integrity, the skeleton needs to constantly remodel and repair the microcracks that develop both in cancellous bone, the “spongy” bone present in the vertebrae, pelvis, and metaphyses of long bones, and in cortical bone, the “compact” bone present in the diaphysis of the long bones and surrounding the cancellous bone in the vertebrae and pelvis.

Osteoporosis is a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue with a subsequent increase in bone fragility and susceptibility to fractures [13, 14].

Skeletal fragility can result from failure to produce a skeleton of optimal mass and strength during growth; excessive bone resorption resulting in decreased bone mass and microarchitectural deterioration of the skeleton; or inadequate response to increased resorption during bone remodeling [15].

The process of bone remodeling occurs in basic multicellular units (BMUs) which include OCs, OBs, and osteocytes and begins with the activation of hematopoietic precursors to become OCs, which normally requires an interaction with cells of the OB lineage.

OCs are members of the monocyte-macrophage family and are derived from the fusion of marrow-derived mononuclear phagocyte, the OC precursors (OCPs), which circulate in peripheral blood (PB) [16]. These cells differentiate under the influence of two cytokines, namely, macrophage colony stimulating factor (M-CSF) and receptor activator of nuclear factor k-B ligand (RANKL). RANKL expressed on OBs and stromal cells as a membrane-bound protein and cleaved into a soluble molecule (sRANKL) by metalloproteinase [17] promotes differentiation and fusion of OCPs and activates mature OCs to reabsorb bone by binding to its specific receptor RANK. Osteoprotegerin (OPG), a soluble decoy receptor secreted by OBs and bone marrow stromal cells, competes with RANK in binding to RANKL, preventing its osteoclastogenic effect [17].

Mature multinucleated bone resorbing OCs are recognized by the expression of key OC markers including TRAP [18], calcitonin receptors [19], cathepsin K [20], pp60c-src [21], matrix metalloproteinase 9 (MMP9) [22], and the alpha V beta 3 integrin chains [23, 24].

Because the resorption and reversal phases of bone remodeling are short and the period required for OB replacement of the bone is long, any increase in the rate of bone remodeling will result in a loss of bone mass [15]. Moreover, the larger number of unfilled Howship's lacunae and Haversian canals will weaken the bone, and excessive resorption can also result in complete loss of trabecular structures, preventing bone formation.

Aside from postmenopausal osteoporosis which affects 30% of woman, there are many causes of secondary osteoporosis which occurs in almost 30–60% of men and more than 50% of premenopausal women [25]. Osteoporosis in children may be primary due to an intrinsic bone abnormality (usually genetic in origin) or secondary due to an underlying medical condition and/or its treatment. The most common condition in the former category is osteogenesis imperfecta in which there is an underlying abnormality in bone matrix composition, usually due to defective synthesis of type I collagen.

Instead, osteoporosis circumscripta, characterized by focal osteolytic lesions [26], is a peculiar condition of Paget's disease, a skeletal disorder which affects 1-2% of adults over 50 [27, 28].

The evaluation of subjects presenting with osteoporosis should include a detailed history, physical exam, and laboratory testing for secondary causes of osteoporosis, according to the guidelines of the American Association of Clinical Endocrinologists (AACE) [29].

3. Postmenopausal Osteoporosis

The decline of ovarian function at menopause results in decreased production of estrogen and a parallel increase in FSH levels. The combined effects of estrogen deprivation and raising FSH production cause a marked stimulation of bone resorption and a period of rapid bone loss which is central for the onset of postmenopausal osteoporosis [30]. Several risk factors are implicated in favoring postmenopausal bone loss. Important nonmodifiable predictors of bone demineralization are age, sex, period of amenorrhea [31, 32], and parental history of fracture [33]. Important modifiable factors are dietary calcium intake [34, 35], low body mass index [31, 36, 37], smoking [3840], reduced physical activity [41, 42], and high alcohol intake [43].

3.1. Estrogen Effects on Bone Remodeling

Estrogen is the major hormonal regulators of bone metabolism in women and men. Estrogen inhibits the activation of bone remodeling, most likely via the osteocytes, and also inhibits bone resorption, largely by direct actions on OCs, but also by modulation of OB/osteocyte and T-cell regulation of OC formation and activity [44].

The direct effects of estrogen on OCs include the induction of OC apoptosis and the inhibition of OC formation. In particular, this hormone inhibits OC formation decreasing the responsiveness of OCPs to the osteoclastogenic cytokine RANKL [45]. Moreover, estrogen inhibits RANKL-stimulated osteoclastic differentiation of human monocytes by inducing estrogen receptor α (ERα) binding to a scaffolding protein, BCAR1; the ERα/BCAR1 complex then sequesters TNF receptor-associated factor 6 (TRAF6), leading to decreased activation of NF-κB and impaired RANKL-induced osteoclastogenesis [46].

In addition to these direct effects on OCs, estrogen also appears to regulate OC formation and activity indirectly. Combined in vitro and in vivo studies have demonstrated that estrogen suppresses RANKL production by OBs and T and B cells [47] and also increases production of the decoy receptor for RANKL, OPG [48].

In mouse models, estrogen modulates the production of a number of bone-resorbing cytokines, including interleukin (IL)-1, IL-6, tumor necrosis factor-α (TNF-α), M-CSF, and prostaglandins [4953]. Thus, this indirect pathway may play a more important role in regulating the effect of estrogen on OC development, and estrogen deficiency induces bone loss by upregulating cytokine production in immune cells [54].

Regarding the role of estrogen on OBs, it has been demonstrated that they inhibit OB apoptosis and increase OB lifespan [55].

3.2. Estrogen-Deficiency Effects on Bone Remodeling: The Role of Immune System

Estrogen deficiency increases OC formation by increasing haematopoietic progenitors and providing a larger recruited OCP pool [5658]. The upregulated formation and activation of OCs lead to cortical porosity and enlarged resorption areas in trabecular surfaces [13, 14]. In addition, estrogen depletion also increases the life span of OCs, and this event leads to prolonged bone loss, deeper resorption cavities, and trabecular perforation increasing the fragility of bone. This event contributes to a longer and slower period of bone wasting following acute phase of bone loss [14]. The bone loss is partly compensated by increase of bone formation due to the increased osteoblastogenesis. This event is fueled by increasing the number of mesenchymal progenitors capable of committing to the OB lineage and thus promotes proliferation of early OB precursors [56, 59, 60]. The net increase of bone formation, however, is limited by increasing apoptosis of OBs induced by estrogen deprivation [55, 61]. Therefore, although estrogen deficiency increases the bone remodeling intensity, there is an imbalance between bone resorption and bone formation [15, 62]. However, the mechanism by which estrogen deficiency induces bone loss seems more complicated, and interplay between estrogen deficiency and immune cells may play a pivotal role in regulating bone absorption in postmenopausal osteoporosis. In fact, estrogen is a well-known regulator of the immune system and T-cell functions [63, 64].

In this respect, studies on humans are few, and the majority of the data have been derived from animal models and cellular cultures, but no consensual picture has emerged from these models.

In one of the most interesting studies surface RANKL expression was quantified by two-color flow cytometry on isolated bone marrow mononuclear cells derived from premenopausal women, early postmenopausal women, and age-matched, estrogen-treated postmenopausal women. The surface concentration of RANKL per cell was increased in postmenopausal women compared to premenopausal women and estrogen-treated postmenopausal women by two- to threefold for MSCs, T cells, B cells, and total RANKL expressing cells [47]. This study suggests that osteoclastogenic RANKL production by T cells and B cells may contribute to bone loss during estrogen deficiency in humans, and it is supported by a recent work on mouse model [65].

Another clinical study underlines the role of T cells in the human postmenopausal bone loss.

This work reported that women with postmenopausal osteoporosis exhibit an increased T-cell activity and elevated production of TNFα and RANKL compared to healthy postmenopausal controls inducing OC formation and activity [12]. In particular, flow cytometry showed a higher percentage of OC precursors (CD14+/CD11b+/VNR+cells) from peripheral blood mononuclear cells (PBMCs) of postmenopausal women with osteoporosis than in the control groups. The mean fluorescence intensity (MFI) of CD11b and VNR was higher in patients than in samples from the control groups, while the MFI of CD14 was higher in the premenopausal controls and inversely correlated with age. This finding suggests that OCPs in patients were more committed toward osteoclastic lineage as compared to controls [12].

Recent clinical studies reported that postmenopausal women had a significantly higher concentration of circulating sclerostin than premenopausal women, and that serum sclerostin levels were inversely correlated with the free estrogen index in postmenopausal women [66]. In vivo and in vitro studies suggest that TNF-α, which is increased in estrogen deficiency, may stimulate the expression of sclerostin via the MEF2 transcription factor. Thus, the increase of sclerostin mediated by TNF-α may at least partially contribute to the pathogenesis of postmenopausal osteoporosis [67].

A recent study provides evidence that IL-17—a member of Th17 cytokine—promotes bone loss by favoring OC production and inhibiting OB differentiation, whose production is under the negative regulation of estrogen [68]. Moreover, an inhibition of IL-17 having bone sparing effect under ovariectomy by antibody approach could form the basis for using humanized antibody against this cytokine towards the treatment of postmenopausal osteoporosis [68].

3.3. B Lymphocyte Alterations in Postmenopausal Osteoporosis

B-cell alterations are well documented during aging and estrogen deficiency, but less is known on B lymphocyte status during osteoporosis. Recently, increasing evidence emerged on an intimate link between B lymphocytes and bone metabolism [69].

Although all women experience menopause and estrogen deficiency, only one third of them suffer from osteoporosis. In a recent study, Breuil et al. studied the phenotypic and functional characteristics of immune cells of 26 postmenopausal women with osteoporotic fractures compared to 24 healthy controls similar for age and estrogen level [54]. They observed, for the first time, a reduction of B lymphocyte number (in particular: B lymphocytes (CD19+), memory B lymphocytes (CD19+/CD27+), memory B lymphocytes expressing CD38 (CD19+/CD27+/CD5−/CD38+), and RANK+ memory B (CD19+/CD27+/RANK+) lymphocytes) in osteoporotic women negatively correlated with BMD. The authors postulated that this modifications of B-cell populations in osteoporotic women are the consequences of the physical changes, which took place in the bone marrow microenvironment, independently from age and estrogen status. Moreover, as memory B lymphocytes play a major role in the immune response to infections, the modifications of B lymphocytes may partly contribute to the increased morbidity and mortality observed after OP fracture [70].

4. Therapeutic Strategies of Postmenopausal Osteoporosis

The treatment of osteoporosis aims to reduce the incidence of vertebral and nonvertebral fractures responsible for the disease-associated morbidity [71] and stabilize or increase bone mass and strength [72].

The two main pharmacological approaches to osteoporosis are the anticatabolic and anabolic therapy, which, respectively, decrease bone resorption [73] and stimulate new bone formation [74].

The anticatabolic agents comprise bisphosphonates: etidronate, alendronate, risedronate, and zoledronic acid; estrogen and the selective estrogen receptor modulator (SERM) raloxifene; salmon calcitonin; and denosumab. The only anabolic agent currently available is teriparatide [75]. The treatment with bisphosphonates reduces fracture risk, not shown for other available agents. Bisphosphonates accumulate in the mineral phase of bone and reduce OC activity by inhibiting farnesyl pyrophosphate synthase [76]. They can be administered orally (daily, weekly, or monthly) or iv (quarterly or yearly). Since their initial introduction in the United States in 1995, questions have been raised about their association with possible side effects (osteonecrosis of the jaw, musculoskeletal pain, atrial fibrillation, atypical fractures, and esophageal cancer) that appear to be rare and may not be causally related [77]. However, for most patients with osteoporosis, the benefits of treatment outweigh the risks. A new therapeutic advance in the treatment of osteoporosis is denosumab, a fully human monoclonal antibody to soluble RANKL [78]. Denosumab is the newest antiresorptive agent, with a novel mechanism of action [79]. It acts like OPG, preventing RANKL from binding to OC receptor RANK; as a result, OC recruitment, maturation, and action are inhibited and bone resorption decreases. Unlike bisphosphonates, denosumab does not accumulate in bone. It has a circulatory half-life of approximately 26 days, and like other monoclonal antibodies, the clearance of denosumab is through the reticuloendothelial system and does not depend on renal clearance [80].

5. Conclusions

In the last years, many studies has been made to understand how the immune system impacts and regulates the skeleton in physiological and pathological conditions through the immunoskeletal interface. Although the majority of data derived from studies on animal models, recently new evidence of the crosstalk between immune system and bone has been accumulated in humans in many disease such as postmenopausal osteoporosis.

These data demonstrate that bone loss induced by estrogen deficiency in menopause is a complex effect of a multitude of pathways and cytokines working in a cooperative fashion to regulate osteoclastogenesis and osteoblastogenesis. Among these cytokines, RANKL and TNFα seem to play a central role inducing OC formation and activity, while IL-17 promotes bone loss by favoring OC production and inhibiting OB differentiation.

These discoveries have potential for developing new therapeutic strategies for the treatment of these bone disorders. In this respect, denosumab, a fully human monoclonal antibody to soluble RANKL, represents a new therapeutic advance in the treatment of osteoporosis with a novel mechanism of action that leads to the decrease of bone resorption and fracture risk.

Conflict of Interests

The authors declare that they have no conflict of interests.


1. Clowes JA, Riggs BL, Khosla S. The role of the immune system in the pathophysiology of osteoporosis. Immunological Reviews. 2005;208:207–227. [PubMed]
2. Ginaldi L, Di Benedetto MC, De Martinis M. Osteoporosis, inflammation and ageing. Immunity and Ageing. 2005;2, article 14
3. Arron JR, Choi Y. Bone versus immune system. Nature. 2000;408(6812):535–536. [PubMed]
4. Kotake S, Udagawa N, Hakoda M, et al. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis & Rheumatism. 2001;44:1003–1012. [PubMed]
5. Roato I, Grano M, Brunetti G, et al. Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement. FASEB Journal. 2005;19(2):228–230. [PubMed]
6. Roato I, Brunetti G, Gorassini E, et al. IL-7 up-regulates TNF-α-dependent osteoclastogenesis in patients affected by solid tumor. PLoS ONE. 2006;1(1, article e124) [PMC free article] [PubMed]
7. Brunetti G, Colucci S, Pignataro P, et al. T cells support osteoclastogenesis in an in vitro model derived from human periodontitis patients. Journal of Periodontology. 2005;76(10):1675–1680. [PubMed]
8. Colucci S, Brunetti G, Cantatore FP, et al. Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNFα, and IL-7 in an in vitro model derived from human psoriatic arthritis. Journal of Pathology. 2007;212(1):47–55. [PubMed]
9. Faienza MF, Brunetti G, Colucci S, et al. Osteoclastogenesis in children with 21-hydroxylase deficiency on long-term glucocorticoid therapy: the role of receptor activator of nuclear factor-κB ligand/osteoprotegerin imbalance. Journal of Clinical Endocrinology and Metabolism. 2009;94(7):2269–2276. [PubMed]
10. Brunetti G, Faienza MF, Picente L, et al. High dickkopf-1 levels in sera and leukocytes from children with 21-hydroxylase deficiency on chronic glucocorticoid treatment. American Journal of Physiology. 2013;304:546–554. [PubMed]
11. Ventura A, Brunetti G, Colucci S, et al. Glucocorticoid-induced osteoporosis in children with 21-hydroxylase deficiency. BioMed Research International. 2013;2013:8 pages.250462 [PMC free article] [PubMed]
12. D’Amelio P, Grimaldi A, Di Bella S, et al. Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis. Bone. 2008;43(1):92–100. [PubMed]
13. McNamara LM. Perspective on post-menopausal osteoporosis: establishing an interdisciplinary understanding of the sequence of events from the molecular level to whole bone fractures. Journal of the Royal Society Interface. 2010;7(44):353–372. [PMC free article] [PubMed]
14. Lerner UH. Bone remodeling in post-menopausal osteoporosis. Journal of Dental Research. 2006;85(7):584–595. [PubMed]
15. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. The Journal of Clinical Investigation. 2005;115(12):3318–3325. [PMC free article] [PubMed]
16. Massey HM, Flanagan AM. Human osteoclasts derive from CD14-positive monocytes. British Journal of Haematology. 1999;106(1):167–170. [PubMed]
17. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423(6937):337–342. [PubMed]
18. Helfrich MH, Thesingh CW, Mieremet RHP, van Iperen-van Gent AS. Osteoclast generation from human fetal bone marrow in cocultures with murine fetal long bones. A model for in vitro study of human osteoclast formation and function. Cell and Tissue Research. 1987;249(1):125–136. [PubMed]
19. Takahashi N, Akatsu T, Udagawa N, et al. Osteoblastic cells are involved in osteoclast formation. Endocrinology. 1988;123(5):2600–2602. [PubMed]
20. Inaoka T, Bilbe G, Ishibashi O, Tezuka KI, Kumegawa M, Kokubo T. Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone. Biochemical and Biophysical Research Communications. 1995;206(1):89–96. [PubMed]
21. Boyce BF, Yoneda T, Lowe C, Soriano P, Mundy GR. Requirement of pp60(c-src) expression for osteoclasts to form ruffled borders and resorb bone in mice. The Journal of Clinical Investigation. 1992;90(4):1622–1627. [PMC free article] [PubMed]
22. Hentunen TA, Jackson SH, Chung H, et al. Characterization of immortalized osteoclast precursors developed from mice transgenic for both bcl-X(L) and simian virus 40 large T antigen. Endocrinology. 1999;140(7):2954–2961. [PubMed]
23. Clover J, Dodds RA, Gowen M. Integrin subunit expression by human osteoblasts and osteoclasts in situ and in culture. Journal of Cell Science. 1992;103(1):267–271. [PubMed]
24. Teitelbaum SL. The osteoclast and its unique cytoskeleton. Annals of the New York Academy of Sciences. 2011;1240:14–17. [PubMed]
25. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. Journal of the American Medical Association. 2001;285(6):785–795. [PubMed]
26. Britton C, Walsh J. Paget disease of bone—an update. Australian Family Physician. 2012;41:100–103. [PubMed]
27. Kanis JA. Pathophysiology and Treatment of Paget’s Disease of Bone. London, UK: Martin Dunitz; 1998.
28. Brunetti G, Marzano F, Colucci S, et al. Genotype-phenotype correlation in juvenile Paget disease: role of molecular alterations of the TNFRSF11B gene. Endocrine. 2012;42:266–271. [PubMed]
29. Watts NB, Bilezikian JP, Camacho PM, AACE Osteoporosis Task Force American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocrine Practice. 2010;16(supplement 3):1–37. [PubMed]
30. Riggs BL, Khosla S, Melton LJ., III Sex steroids and the construction and conservation of the adult skeleton. Endocrine Reviews. 2002;23(3):279–302. [PubMed]
31. Mohamed EI, Tarantino U, Promenzio L, De Lorenzo A. Predicting bone mineral density of postmenopausal healthy and cirrhotic Italian women using age and body mass index. Acta Diabetologica. 2003;40(supplement 1):S23–S28. [PubMed]
32. Kanis JA, Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporosis International. 2005;16(3):229–238. [PubMed]
33. Kanis JA, Johansson H, Oden A, et al. A family history of fracture and fracture risk: a meta-analysis. Bone. 2004;35(5):1029–1037. [PubMed]
34. Shea B, Wells G, Cranney A, et al. WITHDRAWN: calcium supplementation on bone loss in postmenopausal women. Cochrane Database of Systematic Reviews. 2007;(3)CD004526 [PubMed]
35. Tussing L, Chapman-Novakofski K. Osteoporosis prevention education: behavior theories and calcium intake. Journal of the American Dietetic Association. 2005;105(1):92–97. [PubMed]
36. Prentice A. Diet, nutrition and the prevention of osteoporosis. Public Health Nutrition. 2004;7(1):227–243. [PubMed]
37. Knoke JD, Barrett-Connor E. Weight loss: a determinant of hip bone loss in older men and women: The Rancho Bernardo Study. American Journal of Epidemiology. 2003;158(12):1132–1138. [PubMed]
38. Broussard DL, Magnus JH. Risk assessment and screening for low bone mineral density in a multi-ethnic population of women and men: does one approach fit all? Osteoporosis International. 2004;15(5):349–360. [PubMed]
39. Liu X, Kohyama T, Kobayashi T, et al. Cigarette smoke extract inhibits chemotaxis and collagen gel contraction mediated by human bone marrow osteoprogenitor cells and osteoblast-like cells. Osteoporosis International. 2003;14(3):235–242. [PubMed]
40. Lee LL, Lee JSC, Waldman SD, Casper RF, Grynpas MD. Polycyclic aromatic hydrocarbons present in cigarette smoke cause bone loss in an ovariectomized rat model. Bone. 2002;30(6):917–923. [PubMed]
41. Ford MA, Bass MA, Turner LW, Mauromoustakos A, Graves BS. Past and recent physical activity and bone mineral density in college-aged women. Journal of Strength and Conditioning Research. 2004;18(3):405–409. [PubMed]
42. Asikainen TM, Kukkonen-Harjula K, Miilunpalo S. Exercise for health for early postmenopausal women: a systematic review of randomised controlled trials. Sports Medicine. 2004;34(11):753–778. [PubMed]
43. Kim MJ, Shim MS, Kim MK, et al. Effect of chronic alcohol ingestion on bone mineral density in males without liver cirrhosis. The Korean Journal of Internal Medicine. 2003;18(3):174–180. [PubMed]
44. Oursler MJ, Osdoby P, Pyfferoen J, Riggs BL, Spelsberg TC. Avian osteoclasts as estrogen target cells. Proceedings of the National Academy of Sciences of the United States of America. 1991;88(15):6613–6617. [PubMed]
45. Srivastava S, Toraldo G, Weitzmann MN, Cenci S, Ross FP, Pacifici R. Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation. The Journal of Biological Chemistry. 2001;276(12):8836–8840. [PubMed]
46. Robinson LJ, Yaroslavskiy BB, Griswold RD, et al. Estrogen inhibits RANKL-stimulated osteoclastic differentiation of human monocytes through estrogen and RANKL-regulated interaction of estrogen receptor-α with BCAR1 and Traf6. Experimental Cell Research. 2009;315(7):1287–1301. [PMC free article] [PubMed]
47. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. The Journal of Clinical Investigation. 2003;111(8):1221–1230. [PMC free article] [PubMed]
48. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology. 1999;140(9):4367–4370. [PubMed]
49. Manolagas SC, Jilka RL. Mechanisms of disease: bone marrow, cytokines, and bone remodeling—emerging insights into the pathophysiology of osteoporosis. The New England Journal of Medicine. 1995;332(5):305–311. [PubMed]
50. Tanaka S, Takahashi N, Udagawa N, et al. Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. The Journal of Clinical Investigation. 1993;91(1):257–263. [PMC free article] [PubMed]
51. Kimble RB, Vannice JL, Bloedow DC, et al. Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats. The Journal of Clinical Investigation. 1994;93(5):1959–1967. [PMC free article] [PubMed]
52. Ammann P, Rizzoli R, Bonjour JP, et al. Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency. The Journal of Clinical Investigation. 1997;99(7):1699–1703. [PMC free article] [PubMed]
53. Kimble RB, Srivastava S, Ross FP, Matayoshi A, Pacifici R. Estrogen deficiency increases the ability of stromal cells to support murine osteoclastogenesis via an interleukin-1-and tumor necrosis factor- mediated stimulation of macrophage colony-stimulating factor production. The Journal of Biological Chemistry. 1996;271(46):28890–28897. [PubMed]
54. Breuil V, Ticchioni M, Testa J, et al. Immune changes in post-menopausal osteoporosis: The Immunos Study. Osteoporosis International. 2010;21(5):805–814. [PubMed]
55. Kousteni S, Bellido T, Plotkin LI, et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell. 2001;104(5):719–730. [PubMed]
56. Rosen CJ. Pathogenesis of osteoporosis. Baillière's Best Practice & Research. 2000;14:181–193. [PubMed]
57. Jilka RL, Passeri G, Girasole G, et al. Estrogen loss upregulates hematopoiesis in the mouse: a mediating role of IL-6. Experimental Hematology. 1995;23(6):500–506. [PubMed]
58. Jilka RL, Hangoc G, Girasole G, et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science. 1992;257(5066):88–91. [PubMed]
59. Di Gregorio GB, Yamamoto M, Ali AA, et al. Attenuation of the self-renewal of transit-amplifying osteoblast progenitors in the murine bone marrow by 17β-estradiol. The Journal of Clinical Investigation. 2001;107(7):803–812. [PMC free article] [PubMed]
60. Jilka RL, Takahashi K, Munshi M, Williams DC, Roberson PK, Manolagas SC. Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow evidence for autonomy from factors released during bone resorption. The Journal of Clinical Investigation. 1998;101(9):1942–1950. [PMC free article] [PubMed]
61. Kousteni S, Han L, Chen JR, et al. Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids. The Journal of Clinical Investigation. 2003;111(11):1651–1664. [PMC free article] [PubMed]
62. Bord S, Beavan S, Ireland D, Horner A, Compston JE. Mechanisms by which high-dose estrogen therapy produces anabolic skeletal effects in postmenopausal women: role of locally produced growth factors. Bone. 2001;29(3):216–222. [PubMed]
63. Weitzmann MN, Pacifici R. T cells: unexpected players in the bone loss induced by estrogen deficiency and in basal bone homeostasis. Annals of the New York Academy of Sciences. 2007;1116:360–375. [PubMed]
64. Straub RH. The complex role of estrogens in inflammation. Endocrine Reviews. 2007;28(5):521–574. [PubMed]
65. Onal M, Xiong J, Chen X, et al. Receptor activator of nuclear factor κB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss. The Journal of Biological Chemistry. 2012;287:29851–29860. [PubMed]
66. Mirza FS, Padhi ID, Raisz LG, Lorenzo JA. Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. Journal of Clinical Endocrinology and Metabolism. 2010;95(4):1991–1997. [PubMed]
67. Kim BJ, Bae SJ, Lee SY, et al. TNF-αmediates the stimulation of sclerostin expression in an estrogen-deficient condition. Biochemical and Biophysical Research Communications. 2012;424:170–175. [PubMed]
68. Tyagi AM, Srivastava K, Mansoori MN, Trivedi R, Chattopadhyay N, Singh D. Estrogen deficiency induces the differentiation of IL-17 secreting Th17 cells: a new candidate in the pathogenesis of osteoporosis. PLoS One. 2012;7(9)e44552 [PMC free article] [PubMed]
69. Boyce BF, Xing L. Bruton and Tec: new links in osteoimmunology. Cell Metabolism. 2008;7(4):283–285. [PubMed]
70. Takayanagi H, Sato K, Takaoka A, Taniguchi T. Interplay between interferon and other cytokine systems in bone metabolism. Immunological Reviews. 2005;208:181–193. [PubMed]
71. Brandão CM, Machado GP, Acurcio Fde A. Pharmacoeconomic analysis of strategies to treat postmenopausal osteoporosis: a systematic review. Revista Brasileira de Reumatologia. 2012;52:924–937. [PubMed]
72. MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Annals of Internal Medicine. 2008;148(3):197–213. [PubMed]
73. Papaioannou A, Morin S, Cheung AM, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. Canadian Medical Association Journal. 2010;182(17):1864–1873. [PMC free article] [PubMed]
74. Rosen CJ, Bilezikian JP. Clinical review 123: hot topic—anabolic therapy for osteoporosis. Journal of Clinical Endocrinology and Metabolism. 2001;86(3):957–964. [PubMed]
75. Belavic JM. Denosumab, (Prolia): a new option in the treatment of osteoporosis. Nurse Practitioner. 2011;36:11–12. [PubMed]
76. Favus MJ. Bisphosphonates for osteoporosis. The New England Journal of Medicine. 2010;363(21):2027–2035. [PubMed]
77. Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. Journal of Clinical Endocrinology and Metabolism. 2010;95(4):1555–1565. [PubMed]
78. Miller PD. A review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis. Therapeutic Advances in Musculoskeletal Disease. 2011;3:271–282. [PMC free article] [PubMed]
79. Moen MD, Keam SJ. Denosumab: a review of its use in the treatment of postmenopausal osteoporosis. Drugs and Aging. 2011;28(1):63–82. [PubMed]
80. Baron R, Ferrari S, Russell RGG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011;48(4):677–692. [PubMed]

Articles from Clinical and Developmental Immunology are provided here courtesy of Hindawi Publishing Corporation